Role of 18 F-Choline PET/CT in guiding biopsy in patients with risen PSA levels and previous negative biopsy for prostate cancer-Reference-Cited by-同舟云学术

Role of 18 F-Choline PET/CT in guiding biopsy in patients with risen PSA levels and previous negative biopsy for prostate cancer

Published:2017-07 Issue:4 Volume:36 Page:241-246
ISSN:2253-654X
Container-title:Revista Española de Medicina Nuclear e Imagen Molecular
language:en
Short-container-title:Revista Española de Medicina Nuclear e Imagen Molecular

Author:

Jiménez Londoño G.A.,García Vicente A.M.,Amo-Salas M.,Fúnez Mayorga F.,López Guerrero M.A.,Talavera Rubio M.P.,Gutierrez Martin P.,González García B.,de la Torre Pérez J.A.,Soriano Castrejón Á.M.

Publisher

Elsevier BV

Subject

Radiology Nuclear Medicine and imaging

Reference32 articles.

1. Guideline of guidelines: prostate cancer screening;Loeb;BJU Int,2014

2. Prostate cancer localization using multiparametric MR imaging: comparison of Prostate Imaging Reporting and Data System (PI-RADS) and Likert scales;Rosenkrantz;Radiology,2013

3. Characterization of prostate lesions as benign or malignant at multiparametric MR imaging: comparison of three scoring systems in patients treated with radical prostatectomy;Vaché;Radiology,2014

4. Prostate cancer localization with 18fluorine fluorocholine positron emission tomography;Kwee;J Urol,2005

5. Imaging prostate cancer with 11C-choline PET/CT;Reske;J Nucl Med,2006

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Value of 18F-fluorocholine PET/CT in predicting response to radical radiotherapy in patients with localized prostate cancer;Clinical and Translational Radiation Oncology;2021-09

2. 18F-choline PET/computed tomography and clinical parameters in the detection of significant prostate cancer in patients with increased prostate-specific antigen levels and previous negative biopsies;Nuclear Medicine Communications;2020-05-08

3. Aportación de la PET/TC con 11 C-colina en la recidiva bioquímica del cáncer de próstata con antígeno específico prostático sérico inferior a 1 ng/ml;Revista Española de Medicina Nuclear e Imagen Molecular;2018-05